Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model

Heyan Li, Shuo Wang, Koichi Takayama, Taishi Harada, Isamu Okamoto, Eiji Iwama, Akiko Fujii, keiichi ota, Noriko Hidaka, Yuko Kawano, Yoichi Nakanishi

研究成果: ジャーナルへの寄稿記事

18 引用 (Scopus)

抄録

Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.

元の言語英語
ページ(範囲)1-8
ページ数8
ジャーナルLung Cancer
88
発行部数1
DOI
出版物ステータス出版済み - 4 1 2015

Fingerprint

Nicotinic Receptors
Nicotine
Heterografts
Non-Small Cell Lung Carcinoma
MAP Kinase Signaling System
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Erlotinib Hydrochloride
Oral Administration
Western Blotting

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

これを引用

Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. / Li, Heyan; Wang, Shuo; Takayama, Koichi; Harada, Taishi; Okamoto, Isamu; Iwama, Eiji; Fujii, Akiko; ota, keiichi; Hidaka, Noriko; Kawano, Yuko; Nakanishi, Yoichi.

:: Lung Cancer, 巻 88, 番号 1, 01.04.2015, p. 1-8.

研究成果: ジャーナルへの寄稿記事

Li, Heyan ; Wang, Shuo ; Takayama, Koichi ; Harada, Taishi ; Okamoto, Isamu ; Iwama, Eiji ; Fujii, Akiko ; ota, keiichi ; Hidaka, Noriko ; Kawano, Yuko ; Nakanishi, Yoichi. / Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. :: Lung Cancer. 2015 ; 巻 88, 番号 1. pp. 1-8.
@article{1adf9946b7ea49d2a0f2e00279a5c546,
title = "Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model",
abstract = "Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.",
author = "Heyan Li and Shuo Wang and Koichi Takayama and Taishi Harada and Isamu Okamoto and Eiji Iwama and Akiko Fujii and keiichi ota and Noriko Hidaka and Yuko Kawano and Yoichi Nakanishi",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.lungcan.2015.01.017",
language = "English",
volume = "88",
pages = "1--8",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model

AU - Li, Heyan

AU - Wang, Shuo

AU - Takayama, Koichi

AU - Harada, Taishi

AU - Okamoto, Isamu

AU - Iwama, Eiji

AU - Fujii, Akiko

AU - ota, keiichi

AU - Hidaka, Noriko

AU - Kawano, Yuko

AU - Nakanishi, Yoichi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.

AB - Given our previously published study, α 1 nicotinic acetylcholine receptor (nAChR) plays an essential role in nicotine-induced cell signaling and nicotine-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) PC9 cells. The aim of this study was to investigate the potential mechanism between nAChR and EGFR for nicotine-induced resistance to EGFR-TKI erlotinib in the NSCLC xenograft model. Materials and methods: We identified the role of nicotine to EGFR/AKT/ERK pathways and to erlotinib-resistance in NSCLC PC9 and HCC827 cells by MTS assay and western blot. Then, we established the PC9 xenograft model with nicotine exposure and treated mice with erlotinib combined with vehicle or nicotine. Results: We confirmed the effects of nicotine on EGFR/AKT/ERK pathways and determined nicotine's potential in preventing from the effect of erlotinib on NSCLC cells. Then, we showed that nicotine exposures can promote tumor growth and induce resistance to erlotinib in the PC9 xenograft model. Our results also indicated that chronic oral administration of nicotine can cause more significant erlotinib-resistance compared with acute i.v. injection of nicotine through activating α 1 nAChR and EGFR pathways. Conclusions: These results suggest that nicotine contributes to the progression and erlotinib-resistance of the NSCLC xenograft model via the cooperation between nAChR and EGFR.

UR - http://www.scopus.com/inward/record.url?scp=84924529316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924529316&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.01.017

DO - 10.1016/j.lungcan.2015.01.017

M3 - Article

C2 - 25670150

AN - SCOPUS:84924529316

VL - 88

SP - 1

EP - 8

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -